ArticleJournal of extracellular vesicles2026
RVG-Modified BMSCs-Derived Small Extracellular Vesicles Loaded With miR-21 Alleviate Neuronal Injury Resulted From Excessive Autophagy via Targeting PTEN/Akt/mTOR Pathway After Cerebral Ischaemia.
Article in Journal of extracellular vesicles, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent advances in research on novel therapeutic mechanisms and strategies for exosome-based treatment of ischemic stroke.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Ischaemic stroke (IS) leads to tragic disability and high adult mortality, while there are limited therapeutic measures for it. Small extracellular vesicles (sEVs) derived from bone marrow mesenchymal stem cells (BMSCs) have been suggested to have satisfactory therapeutic effects on IS by the delivery of their packed microRNA (miRNA). However, systematically administered naïve sEVs are difficult to cross the blood-brain barrier (BBB) and enter the brain parenchyma; also, the low abundance of sEVs cargo miRNAs restricts the possibility of maximising their regulatory functions. Hence, the brain targeting modification and miRNA delivery strategy are crucial for the optimisation of BMSC-sEVs therapeutic effects. In this study, based on sEVs miRNA-seq and analysis of the RNA-seq datasets for ischaemic stroke patients' samples in the GEO database, we identified that miR-21 sharply drops in the ischaemic brain. By the bioengineered BMSCs with RVG-Lamp2b peptide and miR-21-5p overexpression plasmid, RVG-miR21-sEVs were successfully developed. After characterisation of RVG-miR21-sEVs, it showed that RVG-modified sEVs had a high affinity to neurons, and the administration of RVG-miR21-sEVs displayed superior neurological functional rehabilitation and cerebral infarction reduction in the mouse transient middle cerebral artery occlusion (tMCAo) model. Additionally, RVG-miR21-sEVs treatment suppressed neuron autophagy, mitochondria dysfunction and apoptosis after oxygen-glucose deprivation/re-oxygenation (OGD/R) insult. Furthermore, by using dual-luciferase reporter assay, FISH technique, and miR-21 inhibitor and mimics transfection, we validated that the target of miR-21 is PTEN, and the mechanism investigation showed that miR-21 targets the PTEN/Akt/mTOR pathway to antagonise neuronal injury due to excessive autophagy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.